Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Frey

Showing results (451-460 of 475) with videos related to

Pageof 48
Sort By:
Elife|July 11, 2023
<i>SNORD90</i> induces glutamatergic signaling following treatment with monoaminergic antidepressantsRixing Lin, Aron Kos, Juan Pablo Lopez, et al.
Pharmacopsychiatry|June 25, 2024
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 StudyFarhana Islam, Amanda Lisoway, Edward S Oh, et al.
Bipolar Disorders|October 2, 2021
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentationsLakshmi N Yatham, Trisha Chakrabarty, David J Bond, et al.
Bipolar Disorders|March 15, 2018
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorderLakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, et al.
Innovations in Clinical Neuroscience|February 1, 2021
THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND TrialAnthony L Vaccarino, Amir H Kalali, Pierre Blier, et al.
Journal of Psychopharmacology (Oxford, England)|March 6, 2019
Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trialMárcia Kauer-Sant'Anna, Benicio N Frey, Adam Fijtman, et al.
Translational Psychiatry|March 15, 2022
Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trialArun K Tiwari, Clement C Zai, C Anthony Altar, et al.
Journal of Psychiatry & Neuroscience : JPN|March 7, 2019
The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocolsGlenda M. MacQueen, Stefanie Hassel, Stephen R. Arnott, et al.
Translational Psychiatry|May 31, 2022
Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trialArun K Tiwari, Clement C Zai, C Anthony Altar, et al.
Journal of Affective Disorders|January 30, 2024
An empirical analysis of structural neuroimaging profiles in a staging model of depressionNikita Nogovitsyn, Pedro Ballester, Mike Lasby, et al.
Pageof 48

Showing results (451-460 of 475) with videos related to

Sort By:
Pageof 48
Elife|July 11, 2023
<i>SNORD90</i> induces glutamatergic signaling following treatment with monoaminergic antidepressantsRixing Lin, Aron Kos, Juan Pablo Lopez, et al.
Pharmacopsychiatry|June 25, 2024
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 StudyFarhana Islam, Amanda Lisoway, Edward S Oh, et al.
Bipolar Disorders|October 2, 2021
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentationsLakshmi N Yatham, Trisha Chakrabarty, David J Bond, et al.
Bipolar Disorders|March 15, 2018
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorderLakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, et al.
Innovations in Clinical Neuroscience|February 1, 2021
THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND TrialAnthony L Vaccarino, Amir H Kalali, Pierre Blier, et al.
Journal of Psychopharmacology (Oxford, England)|March 6, 2019
Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trialMárcia Kauer-Sant'Anna, Benicio N Frey, Adam Fijtman, et al.
Translational Psychiatry|March 15, 2022
Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trialArun K Tiwari, Clement C Zai, C Anthony Altar, et al.
Journal of Psychiatry & Neuroscience : JPN|March 7, 2019
The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocolsGlenda M. MacQueen, Stefanie Hassel, Stephen R. Arnott, et al.
Translational Psychiatry|May 31, 2022
Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trialArun K Tiwari, Clement C Zai, C Anthony Altar, et al.
Journal of Affective Disorders|January 30, 2024
An empirical analysis of structural neuroimaging profiles in a staging model of depressionNikita Nogovitsyn, Pedro Ballester, Mike Lasby, et al.
Pageof 48